- Home
- MNTK vs TNGX Comparison
MNTK vs TNGX Comparison
Compare MNTK & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNTK
- TNGX
- Stock Information
- Founded
- MNTK 1980
- TNGX 2014
- Country
- MNTK United States
- TNGX United States
- Employees
- MNTK N/A
- TNGX N/A
- Industry
- MNTK Natural Gas Distribution
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- MNTK Utilities
- TNGX Health Care
- Exchange
- MNTK Nasdaq
- TNGX Nasdaq
- Market Cap
- MNTK 306.2M
- TNGX 351.2M
- IPO Year
- MNTK 2021
- TNGX N/A
- Fundamental
- Price
- MNTK $2.32
- TNGX $6.82
- Analyst Decision
- MNTK Hold
- TNGX Strong Buy
- Analyst Count
- MNTK 3
- TNGX 5
- Target Price
- MNTK $3.33
- TNGX $10.50
- AVG Volume (30 Days)
- MNTK 213.0K
- TNGX 2.0M
- Earning Date
- MNTK 08-07-2025
- TNGX 08-05-2025
- Dividend Yield
- MNTK N/A
- TNGX N/A
- EPS Growth
- MNTK N/A
- TNGX N/A
- EPS
- MNTK 0.05
- TNGX N/A
- Revenue
- MNTK $179,552,000.00
- TNGX $40,990,000.00
- Revenue This Year
- MNTK $2.49
- TNGX N/A
- Revenue Next Year
- MNTK $26.02
- TNGX N/A
- P/E Ratio
- MNTK $44.54
- TNGX N/A
- Revenue Growth
- MNTK N/A
- TNGX 10.09
- 52 Week Low
- MNTK $1.68
- TNGX $1.03
- 52 Week High
- MNTK $6.13
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- MNTK 51.91
- TNGX 71.71
- Support Level
- MNTK $2.06
- TNGX $6.36
- Resistance Level
- MNTK $2.35
- TNGX $7.20
- Average True Range (ATR)
- MNTK 0.12
- TNGX 0.47
- MACD
- MNTK 0.01
- TNGX -0.03
- Stochastic Oscillator
- MNTK 59.09
- TNGX 77.91
About MNTK Montauk Renewables Inc.
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.